ALSUntangled #62: vitamin C

Richard Bedlack; Paul Barkhaus; Greg Carter; Jesse Crayle; Christopher Mcdermott; Gary Pattee; Meraida Polak; Kristiana Salmon; Paul Wicks

doi:10.1080/21678421.2021.1946088

ALSUntangled #62: vitamin C

Richard Bedlack, Paul Barkhaus, Greg Carter, Jesse Crayle, Christopher Mcdermott, Gary Pattee, Meraida Polak, Kristiana Salmon, Paul Wicks

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Vitamin C is one of the most common supplements taken by people with ALS. As an antioxidant, it has a plausible mechanism for slowing disease progression and there are some flawed pre-clinical studies and case reports suggesting benefit. However, a small human trial showed no benefit. Given this negative trial, we do not currently advise vitamin C as an ALS treatment.

Original language	English
Pages (from-to)	476-479
Number of pages	4
Journal	Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume	23
Issue number	5-6
DOIs	https://doi.org/10.1080/21678421.2021.1946088
State	Published - 2022

Keywords

Vitamin C
acorbic acid
ascorbate
clinical trials
models
therapy

Access to Document

10.1080/21678421.2021.1946088

Cite this

@article{b64d361c5ff44ed892a3696ec0c1a446,

title = "ALSUntangled #62: vitamin C",

abstract = "Vitamin C is one of the most common supplements taken by people with ALS. As an antioxidant, it has a plausible mechanism for slowing disease progression and there are some flawed pre-clinical studies and case reports suggesting benefit. However, a small human trial showed no benefit. Given this negative trial, we do not currently advise vitamin C as an ALS treatment.",

keywords = "Vitamin C, acorbic acid, ascorbate, clinical trials, models, therapy",

author = "Richard Bedlack and Paul Barkhaus and Greg Carter and Jesse Crayle and Christopher Mcdermott and Gary Pattee and Meraida Polak and Kristiana Salmon and Paul Wicks",

note = "Publisher Copyright: {\textcopyright} 2021 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases.",

year = "2022",

doi = "10.1080/21678421.2021.1946088",

language = "English",

volume = "23",

pages = "476--479",

journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",

issn = "2167-8421",

publisher = "Informa Healthcare",

number = "5-6",

}

TY - JOUR

T1 - ALSUntangled #62

T2 - vitamin C

AU - Bedlack, Richard

AU - Barkhaus, Paul

AU - Carter, Greg

AU - Crayle, Jesse

AU - Mcdermott, Christopher

AU - Pattee, Gary

AU - Polak, Meraida

AU - Salmon, Kristiana

AU - Wicks, Paul

PY - 2022

Y1 - 2022

N2 - Vitamin C is one of the most common supplements taken by people with ALS. As an antioxidant, it has a plausible mechanism for slowing disease progression and there are some flawed pre-clinical studies and case reports suggesting benefit. However, a small human trial showed no benefit. Given this negative trial, we do not currently advise vitamin C as an ALS treatment.

AB - Vitamin C is one of the most common supplements taken by people with ALS. As an antioxidant, it has a plausible mechanism for slowing disease progression and there are some flawed pre-clinical studies and case reports suggesting benefit. However, a small human trial showed no benefit. Given this negative trial, we do not currently advise vitamin C as an ALS treatment.

KW - Vitamin C

KW - acorbic acid

KW - ascorbate

KW - clinical trials

KW - models

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85134444415&partnerID=8YFLogxK

U2 - 10.1080/21678421.2021.1946088

DO - 10.1080/21678421.2021.1946088

M3 - Article

C2 - 34187257

AN - SCOPUS:85134444415

SN - 2167-8421

VL - 23

SP - 476

EP - 479

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

IS - 5-6

ER -

ALSUntangled #62: vitamin C

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this